Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avibactam/aztreonam - AbbVie/AstraZeneca/Pfizer

Next Previous
X
Search
Drug Profile

Avibactam/aztreonam - AbbVie/AstraZeneca/Pfizer

Alternative Names: EMBLAVEO; ATM-AVI; Aztreonam-avibactam; PF-06947387

Latest Information Update: 14 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AbbVie; AstraZeneca; Biomedical Advanced Research and Development Authority; Innovative Medicines Initiative; Pfizer
  • Class Amides; Anti-infectives; Antibacterials; Heterocyclic bicyclo compounds; Monobactams; Small molecules; Sulfates
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Gram-negative infections
  • Phase II Intra-abdominal infections

Most Recent Events

  • 07 Aug 2024 Phase-II clinical trials in Gram-negative infections (In infants, In neonates) in USA (IV) (NCT06462235)
  • 17 Jun 2024 Pfizer in collaboration with AbbVie plans a phase II CHERISH trial in Gram-negative infections (In neonates, In infants) (IV) in September 2024 (NCT06462235) (EudraCT2023-507757-15-00)
  • 23 Apr 2024 Registered for Gram-negative infections in Norway, Liechtenstein, Iceland, European Union (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top